https://mindmedicinelaw.com/briefing/psilocybin-crystal-structure-discovery-implications-for-research-20260901-37657The Psychedelic Journalen2026-09-01T15:05:39.203177+00:00Psilocybin Crystal Structure Discovery: Implications for Researchpsilocybin crystal structure, psychedelic research, molecular properties, clinical formulations, therapeutic mechanisms, stability of psilocybin, pharmaceutical development, regulatory implications, clinical trials, psychedelic medicinehttps://mindmedicinelaw.com/briefing/stanford-s-ketamine-ocd-study-explores-mu-opioid-mechanisms-20260901-37667The Psychedelic Journalen2026-09-01T15:05:22.977203+00:00Stanford's Ketamine OCD Study Explores Mu Opioid Mechanismsketamine, OCD treatment, mu opioid receptors, Stanford Psychiatry, psychiatric disorders, neurobiological pathways, clinical trials, psychedelic research, Carolyn Rodriguez, mental healthhttps://mindmedicinelaw.com/briefing/psychedelic-integration-in-healthcare-biomedical-and-existential-roles-20260831-37630The Psychedelic Journalen2026-09-01T15:06:39.057884+00:00Psychedelic Integration in Healthcare: Biomedical and Existential Rolespsychedelic research, biomedical applications, existential impacts, clinical trials, mental health treatment, public health strategies, regulatory frameworks, neuroplasticity, serotonin receptors, therapeutic protocolshttps://mindmedicinelaw.com/briefing/ketamine-and-psychotherapy-in-mental-health-treatment-20260831-37668The Psychedelic Journalen2026-09-01T15:06:20.605368+00:00Ketamine and Psychotherapy in Mental Health Treatmentketamine, psychotherapy, mental health treatment, synergistic effects, clinical trials, FDA guidelines, treatment protocols, depression therapy, neuroscience, psychotherapy integrationhttps://mindmedicinelaw.com/briefing/breathing-and-neural-oscillations-new-insights-in-neuroscience-20260831-37589The Psychedelic Journalen2026-09-01T15:06:07.331794+00:00Breathing and Neural Oscillations: New Insights in Neurosciencebreathing patterns, neural oscillations, brain-body interactions, mental health therapies, cognitive disorders, neuroscience research, respiration influence, therapeutic approacheshttps://mindmedicinelaw.com/briefing/philadelphia-s-public-health-response-to-medetomidine-20260831-37590The Psychedelic Journalen2026-09-01T15:05:52.926437+00:00Philadelphia's Public Health Response to Medetomidinemedetomidine, Philadelphia, opioid adulterant, public health response, overdose management, clinical recognition, community readiness, substance use treatment, drug supply monitoring, healthcare coordinationhttps://mindmedicinelaw.com/briefing/integrating-psychedelic-and-neuropsychiatric-therapies-a-new-framework-20260831-37581The Psychedelic Journalen2026-09-01T15:05:03.595615+00:00Integrating Psychedelic and Neuropsychiatric Therapies: A New Frameworkpsychedelic therapies, neuropsychiatric disorders, multidisciplinary framework, evidence-based treatment, mechanism of action, treatment protocolshttps://mindmedicinelaw.com/briefing/fda-s-final-debarment-of-rahim-shafa-implications-for-psychedelic-sector-20260831-37193The Psychedelic Journalen2026-08-31T15:05:23.928946+00:00FDA's Final Debarment of Rahim Shafa: Implications for Psychedelic SectorFDA debarment, Rahim Shafa, psychedelic regulation, FD&C Act, drug importation, compliance strategies, pharmaceutical industry, psychedelic research, regulatory enforcement, legal consequenceshttps://mindmedicinelaw.com/briefing/emerging-therapies-for-major-depressive-disorder-challenges-and-opportunities-20260830-37546The Psychedelic Journalen2026-09-01T15:07:23.126239+00:00Emerging Therapies for Major Depressive Disorder: Challenges and Opportunitiesmajor depressive disorder, treatment-resistant depression, neuroplasticity, neurocircuitry, SSRIs, TCAs, mental health treatment, psychiatric therapies, clinical trials, FDAhttps://mindmedicinelaw.com/briefing/mechanisms-of-clbp-and-mdd-comorbidity-implications-for-precision-medicine-20260830-37592The Psychedelic Journalen2026-09-01T15:07:03.112631+00:00Mechanisms of CLBP and MDD Comorbidity: Implications for Precision Medicinechronic low back pain, major depressive disorder, neural-immune interactions, gut-brain axis, precision medicine, clinical trials, neuroinflammation, spinal cord stimulation, electroacupuncture, comorbidity mechanismshttps://mindmedicinelaw.com/briefing/optimizing-ketamine-infusion-for-bipolar-depression-key-insights-20260830-37593The Psychedelic Journalen2026-09-01T15:06:50.459085+00:00Optimizing Ketamine Infusion for Bipolar Depression: Key Insightsketamine infusion, bipolar depression, treatment-resistant, individualized strategies, predictors of response, neurocognitive outcomes, inflammatory correlates, maintenance planning, clinical trials, mental health treatmenthttps://mindmedicinelaw.com/briefing/neuroimaging-study-maps-brain-networks-in-dissociative-symptoms-20260829-37210The Psychedelic Journalen2026-08-31T15:05:48.679361+00:00Neuroimaging Study Maps Brain Networks in Dissociative Symptomsdissociative symptoms, neuroimaging, brain networks, psychiatric disorders, psychedelic research, neurotransmitter associations, therapeutic interventions, clinical trialshttps://mindmedicinelaw.com/briefing/neurophysiological-insights-from-meditation-in-tibetan-monks-20260829-37246The Psychedelic Journalen2026-08-31T15:05:34.904218+00:00Neurophysiological Insights from Meditation in Tibetan Monksneurophysiological signatures, meditation practices, Tibetan monks, autonomic-cortical integration, mental health benefits, study design limitations, emotional regulation, cognitive flexibility, EEG analysis, parasympathetic activityhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-treatment-resistant-depression-mechanisms-and-implications-20260828-37258The Psychedelic Journalen2026-08-31T15:06:00.079434+00:00Ketamine's Role in Treatment-Resistant Depression: Mechanisms and Implicationsketamine, treatment-resistant depression, glutamatergic neurotransmission, neuroplasticity, NMDA receptors, AMPA receptors, BDNF signaling, mTOR pathways, antidepressant effectshttps://mindmedicinelaw.com/briefing/mdma-therapy-for-ptsd-systematic-review-insights-20260828-37230The Psychedelic Journalen2026-08-31T15:05:08.898954+00:00MDMA Therapy for PTSD: Systematic Review InsightsMDMA-assisted therapy, PTSD treatment, depressive symptoms, systematic review, clinical guidelines, psychedelic research, mental health, FDA approval, psychedelic-assisted therapy, public healthhttps://mindmedicinelaw.com/briefing/5-meo-dmt-s-potential-in-treating-depression-a-new-frontier-20260827-37829The Psychedelic Journalen2026-09-01T22:04:04.539910+00:005-MeO-DMT's Potential in Treating Depression: A New Frontier5-MeO-DMT, treatment-resistant depression, psychedelic therapy, serotonin receptors, psychedelic research, mental health treatment, regulatory considerations, clinical trials, safety and efficacy, psychological experiences